FDA to assess whether saxagliptin raises heart risks

02/12/2014 | Reuters

The FDA is set to evaluate potential heart risks linked to the diabetes drug saxagliptin by AstraZeneca. The FDA will consider the issue after the drugmaker submits data from clinical trials, expected by early March. The investigation follows publication of research in the New England Journal of Medicine that revealed saxagliptin-treated patients showed a slight increase in heart failure admissions.

View Full Article in:


Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Mylan Inc.
Washington, DC
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director of Actuarial Services, Government Programs
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC